The Drug Resistance Mechanism of Liver Cancer Stem Cells in Sorafenib Treatment
碩士 === 東海大學 === 生命科學系 === 106 === Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and comprises more than 90% of human liver cancers. Surgical resection is the best treatment for HCC, but only about 15% of patients are suitable for this treatment. To the unresectable or m...
Main Authors: | LIAO, CHEN-CHUN, 廖振群 |
---|---|
Other Authors: | CHAO, WEI-TING |
Format: | Others |
Language: | zh-TW |
Published: |
2018
|
Online Access: | http://ndltd.ncl.edu.tw/handle/jbqj4q |
Similar Items
-
The Roles Of Angiogenesis And Cancer Stem Cells In Sorafenib Drug Resistance In Hepatocellular Carcinoma
by: Cheng CC, et al.
Published: (2019-10-01) -
Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells
by: Ritu Shrestha, et al.
Published: (2021-06-01) -
Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer
by: Judith Knievel, et al.
Published: (2014-11-01) -
GINS1 Induced Sorafenib Resistance by Promoting Cancer Stem Properties in Human Hepatocellular Cancer Cells
by: Sheng Li, et al.
Published: (2021-08-01) -
CXCR4-Targeted Lipid-Coated PLGA Nanoparticles Deliver Sorafenib and Overcome Acquired Drug Resistance in Liver Cancer
by: Gao, Dong-Yu, et al.
Published: (2015)